-
Founded in:
1989-08-22 -
Country:
China -
Address:
No. 2003, Shenyan Road, Shatoujiao, Yantian District, Shenzhen -
Tax NO.:
91440300618855174Y -
Registered Funds:
700 million yuan -
Website:
-
Email:
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Gynostemma pentaphyllumsaponins |
Significantly reduce serum lipids (including total cholesterol, triglycerides, low-density lipoprotein) and increase serum high-density lipoprotein; prevent lipid deposition in blood vessel walls, improve immune function, and inhibit the side effects caused by glucocorticoids.
More
Significantly reduce serum lipids (including total cholesterol, triglycerides, low-density lipoprotein) and increase serum high-density lipoprotein; prevent lipid deposition in blood vessel walls, improve immune function, and inhibit the side effects caused by glucocorticoids. |
0 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Famotidine |
Histamine H2 receptor antagonist, which has an inhibitory effect on the secretion of gastric acid and pepsin and can reduce the production of gastric acid
More
Histamine H2 receptor antagonist, which has an inhibitory effect on the secretion of gastric acid and pepsin and can reduce the production of gastric acid |
10mg | 76824-35-6 | 69 |
| Calcium carbonate |
Antacids, which neutralize stomach acid that has already been produced
More
Antacids, which neutralize stomach acid that has already been produced |
800mg | 471-34-1 | 43 |
| Magnesium hydroxide |
Antacids, which neutralize stomach acid that has already been produced
More
Antacids, which neutralize stomach acid that has already been produced |
165mg | 1309-42-8 | 20 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Imipenem |
|
64221-86-9 | 7 | |
| Cilastatin |
|
82009-34-5 | 2 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| RN,N-diisopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropylamine-L-(+)-tartrate |
Competitive M cholinergic receptor blocker, used to relieve symptoms of frequent urination, urgency and urgency incontinence caused by overactive bladder. It has higher selectivity for bladder than salivary glands (suggested by animal experiments, but not yet clinically confirmed). After oral administration, it is metabolized by the liver into active metabolites 5-hydroxymethyl derivatives, both of which are highly selective for M cholinergic receptors and have very weak effects or affinity on other neurotransmitter receptors and cell targets.
More
Competitive M cholinergic receptor blocker, used to relieve symptoms of frequent urination, urgency and urgency incontinence caused by overactive bladder. It has higher selectivity for bladder than salivary glands (suggested by animal experiments, but not yet clinically confirmed). After oral administration, it is metabolized by the liver into active metabolites 5-hydroxymethyl derivatives, both of which are highly selective for M cholinergic receptors and have very weak effects or affinity on other neurotransmitter receptors and cell targets. |
0 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| RN,N-diisopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropylamine-L-(+)-tartrate |
Competitive M cholinergic receptor blocker, used to relieve symptoms of frequent urination, urgency and urgency incontinence caused by overactive bladder. It has higher selectivity for bladder than salivary glands (animal test results suggest, but not yet clinically confirmed). After oral administration, it is metabolized by the liver into the active metabolite 5-hydroxymethyl derivative, which has the main pharmacological effect, and its anticholinergic activity is similar to that of this product. Both are highly selective for M cholinergic receptors, and have very weak effects or affinity on receptors of other neurotransmitters and potential cell targets.
More
Competitive M cholinergic receptor blocker, used to relieve symptoms of frequent urination, urgency and urgency incontinence caused by overactive bladder. It has higher selectivity for bladder than salivary glands (animal test results suggest, but not yet clinically confirmed). After oral administration, it is metabolized by the liver into the active metabolite 5-hydroxymethyl derivative, which has the main pharmacological effect, and its anticholinergic activity is similar to that of this product. Both are highly selective for M cholinergic receptors, and have very weak effects or affinity on receptors of other neurotransmitters and potential cell targets. |
0 |